Agenus Stock News

Agenus (AGEN) and Targovax ASA signed a clinical collaboration and supply agreement to combine Targovax’s TG mutant KRAS cancer vaccines with Agenus'' QS-21 STIMULON adjuvant technology

LEXINGTON, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, adjuvants, and vaccines designed to activa

Gainers ECMOHO Limited (NASDAQ: MOHO ) climbed 56.7% to close at $0.3650 on Wednesday after jumping 10% on Tuesday. Imperial Petroleum Inc. (NASDAQ: IMPP ) shares jumped 39.2% to close at $2.06 after dipping 37% on Tuesday. Nordstrom, Inc. (NYSE: JWN ) shares jumped 37.8% to settle at $26.93 after the company reported better-than-expected Q4 EPS and sales results. The company also issued FY22 guidance. Regulus Therapeutics Inc. (NASDAQ: RGLS ) gained 35.6% to close at $0.3050. Indonesia Energy Corporation Limited (NASDAQ: INDO ) surged 34.5% to close at $14.50. Trevi Therapeutics, Inc. (NASDAQ: TRVI ) gained 32% to settle at $1.15. Arlo Technologies, Inc. (NYSE: ARLO ) rose 28.9% to close at $11.19 after the company reported better-than-expected Q4 results. The company also issued Q1 sales guidance above analyst estimates. Rocky Brands, Inc. (NASDAQ: RCKY ) climbed 26.6% to close at $47.47 following better-than-expected Q4 results. China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC ) gained 26.1% to close at $0.2181.

An optimistic analyst upgrade is powering the biotech's shares higher today.

An optimistic analyst upgrade is powering the biotech's shares higher today.

AGEN earnings call for the period ending December 31, 2021.

Agenus (AGEN) delivered earnings and revenue surprises of -62.50% and 46.30%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Agenus press release (AGEN): Q4 GAAP EPS of -$0.26 misses by $0.10.Revenue of $20.26M (-35.2% Y/Y) misses by $17.48M.Shares +1.85% PM.

Agenus' (AGEN) CEO Garo Armen on Q4 2021 Results - Earnings Call Transcript

LEXINGTON, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies and adjuvants designed to activate immune response to cancers and infections, today provided a corporate update and reported financial results for the fourth quarter and full year 2021.

Agenus (AGEN) delivered earnings and revenue surprises of -62.50% and 46.30%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

In today’s recent session, 0.66 million shares of the Agenus Inc. (NASDAQ:AGEN) have been traded, and its beta is 1.18. Most recently the company’s share price was $2.47, and it changed around $0.12 or 5.11% from the last close, which brings the market valuation of the company to $623.34M. AGEN at last check was trading … Why Agenus Inc. (NASDAQ: AGEN) Is A Stock Not To Be Discarded In 2022 Read More »

Agenus: Making Another Effort With The FDA